Innoviva Management to Present at Goldman Sachs Healthcare Conference 2025

Innoviva to Participate in Upcoming Investor Conferences

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

06/03/2025 - 07:00 AM

BURLINGAME, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (鈥淚nnoviva鈥� or the 鈥淐ompany鈥�), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (鈥淚ST鈥�), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June:

Goldman Sachs 46th Annual Global Healthcare Conference 2025
Format: Fireside chat
Date: Monday, June 9, 2025
Time: 1:20 p.m. Eastern Time

Scotiabank Third Annual Healthcare Canadian Investor Day
Format: 1x1 meetings
Date: Tuesday, June 17, 2025

A live webcast of the fireside chat from the Goldman Sachs 46th Annual Global Healthcare Conference 2025 can be accessed under 鈥淓vents & Presentations鈥� in the Investor Relations section of the Company鈥檚 website at . An archived replay of the webcast will be available following the presentation date.

About Innoviva

Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (鈥淚ST鈥�), and a portfolio of strategic investments in healthcare assets. Innoviva鈥檚 royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (鈥淕SK鈥�). Innoviva is entitled to receive royalties from GSK on sales of RELVAR^庐/BREO^庐 ELLIPTA^庐 and ANORO^庐 ELLIPTA^庐. Innoviva鈥檚 other commercial and marketed products include infectious disease and critical care assets: GIAPREZA^庐 (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock; XERAVA^庐 (eravacycline), approved for the treatment of complicated intra-abdominal infections in adults; and XACDURO^庐 (sulbactam for injection; durlobactam for injection), approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. In addition, ZEVTERA^庐 (ceftobiprole), an advanced-generation cephalosporin antibiotic, will be exclusively commercialized by us in the U.S. under a distribution and license agreement with Basilea Pharmaceutica Ltd., (鈥淏asilea鈥�), entered into in December 2024. We continue to advance our pipeline with zoliflodacin, a potentially first in class, single-dose oral treatment for uncomplicated gonorrhea.

ANORO^庐, RELVAR^庐 and BREO^庐 are trademarks of the GSK group of companies. ZEVTERA^庐 is a trademark of Basilea Pharmaceutica Ltd., Allschwil.